Renaissance Capital logo

DNLI News

No trial, no problem: Biggest week for preclinical biotech IPOs ever

PCVX

Three large preclinical biotech IPOs are slated to begin trading on Friday, the most ever in a single week. Vaxcyte (PCVX) is developing next-generation pneumonia vaccines, a $7 billion market, and expects to begin clinical trials for its lead candidate in the 2H21. Avidity Biosciences (RNA) expects to submit an IND in 2021 and begin a...read more

Pushing preclinical: Wave of early-stage biotech IPOs tests investor risk appetite

UBX

Biotechs are among the most risky of IPOs due to the binary nature of the success… or failure of their drugs. In the past, most biotechs delayed public offerings until they at least showed clinical evidence of their safety or efficacy. But in 2018, biotechs are increasingly going public with little or no clinical data. Instead, IPO investors are asked to rely on theories...read more

US IPO Week Ahead: 2018 IPO market kicks off with a quiet week

QTRX

There are no deals set to price in the first week of the new year; however, filing activity will continue from companies targeting 1Q18 IPOs. The IPO market rounded out 2017 at an even 160 IPOs, raising $35.5 billion in total proceeds, nearly double that of 2016. Refer to our 2017 Annual Review for further insights and...read more

US IPO Weekly Recap: Year's largest biotech headlines 6-IPO week

DNLI

Led by the largest biotech IPO since June 2015, six companies raised $827 million this past week. Biotech Denali Therapeutics raised $250 million, making it the largest biotech IPO of year by both deal size and market cap. The week also included pricings from a cancer biotech, a medical diagnostics company, a California bank, a payday lender and a SPAC. No companies priced...read more